



VALEANT — COULD THIS BE THE PHARMACEUTICAL ENRON ?

Citron Publishes the Smoking Gun!!

Price Target lowered to \$50

Just four days ago in the world of Valeant, no one had ever heard of Philidor RX. Recent concerns about the company focused on its unsavory business practices of massive price raises on pharmaceuticals acquired in a rapid succession of acquisitions, while slashing research and development. But no one had discussed how these drugs were distributed....until this week.

Now Valeant has made new disclosures regarding its distribution channel, and they've led the company into a web of deception that ... you have to read for yourselves.

For the Rest of the Story, Click Here:

[\[http://www.citronresearch.com/wp-content/uploads/2015/10/Vfinal-d.pdf\]](http://www.citronresearch.com/wp-content/uploads/2015/10/Vfinal-d.pdf)

ACRUX DDS PTY LTD. et al.
EXHIBIT 1547(a)
IPR Petition for
U.S. Patent No. 7,214,506

OCTOBER 21, 2015 /

Share this entry



© Copyright 2017 - Citron Research | All Rights Reserved | "Cautious Investing To All"